Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
Praxis Precision Medicines (NASDAQ: PRAX) has announced that it will release topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) on September 3, 2024, before the market opens. The study focuses on SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs). Following the announcement, the company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results. This event is significant for Praxis, a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines (NASDAQ: PRAX) ha annunciato che rilascerà i risultati preliminari dello studio di Fase 2 EMBOLD sul relutrigine (PRAX-562) il 3 settembre 2024, prima dell'apertura del mercato. Lo studio si concentra sulle encefalopatie epilettiche e di sviluppo SCN2A e SCN8A (DEE). Dopo l'annuncio, l'azienda organizzerà una chiamata conferenza e una presentazione in webcast alle 8:00 a.m. ET per discutere i risultati della sperimentazione. Questo evento è significativo per Praxis, un'azienda biofarmaceutica in fase clinica che sviluppa terapie per i disturbi del sistema nervoso centrale caratterizzati da uno squilibrio di eccitazione-inibizione neuronale.
Praxis Precision Medicines (NASDAQ: PRAX) ha anunciado que publicará los resultados preliminares del estudio de Fase 2 EMBOLD de relutrigina (PRAX-562) el 3 de septiembre de 2024, antes de la apertura del mercado. El estudio se centra en las encefalopatías de desarrollo y epilépticas SCN2A y SCN8A (DEEs). Tras el anuncio, la compañía llevará a cabo una llamada de conferencia y presentación por webcast a las 8:00 a.m. ET para discutir los resultados del ensayo. Este evento es significativo para Praxis, una empresa biofarmacéutica en etapa clínica que desarrolla terapias para trastornos del sistema nervioso central caracterizados por un desequilibrio de excitación-inhibición neuronal.
프랙시스 프리시전 메디슨스 (NASDAQ: PRAX)는 2024년 9월 3일 시장 개장 전에 relutrigine (PRAX-562)의 2상 EMBOLD 연구의 초록 결과를 발표할 것이라고 발표했습니다. 이 연구는 SCN2A 및 SCN8A 발달 및 간질 뇌병증 (DEEs)에 초점을 맞추고 있습니다. 발표 후, 회사는 오전 8:00 ET에 컨퍼런스 콜 및 웹캐스트 발표를 개최하여 시험 결과를 논의할 것입니다. 이 이벤트는 뉴런의 흥분-억제 불균형을 특징으로 하는 중추 신경계 질환에 대한 치료제를 개발하는 임상 단계의 생물 제약 회사인 프랙시스에 중요합니다.
Praxis Precision Medicines (NASDAQ: PRAX) a annoncé qu'elle publiera les résultats préliminaires de l'étude de Phase 2 EMBOLD sur le relutrigine (PRAX-562) le 3 septembre 2024, avant l'ouverture du marché. L'étude se concentre sur les encéphalopathies développementales et épileptiques SCN2A et SCN8A (DEEs). Suite à cette annonce, la société organisera un appel de conférence et une présentation en webcast à 8h00 ET pour discuter des résultats de l'essai. Cet événement est significatif pour Praxis, une entreprise biopharmaceutique en phase clinique développant des thérapies pour les troubles du système nerveux central caractérisés par un déséquilibre d'excitation-inhibition neuronale.
Praxis Precision Medicines (NASDAQ: PRAX) hat angekündigt, dass am 3. September 2024 vor Markteröffnung die vorläufigen Ergebnisse der Phase 2 EMBOLD-Studie zu Relutrigine (PRAX-562) veröffentlicht werden. Die Studie konzentriert sich auf SCN2A- und SCN8A-Entwicklung- sowie epileptische Enzephalopathien (DEEs). Nach der Ankündigung wird das Unternehmen um 8:00 Uhr ET eine Telefonkonferenz und Webcast-Präsentation abhalten, um die Studienergebnisse zu besprechen. Diese Veranstaltung ist bedeutend für Praxis, ein biopharmazeutisches Unternehmen in der klinischen Phase, das Therapien für Störungen des zentralen Nervensystems entwickelt, die durch ein Ungleichgewicht von neuronaler Erregung und Hemmung gekennzeichnet sind.
- Scheduled release of topline data from a Phase 2 clinical trial
- Focus on potential treatment for rare genetic epilepsies (SCN2A and SCN8A DEEs)
- Transparent communication with investors through conference call and webcast
- None.
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.
Conference Call and Webcast Presentation
Date and Time: Tuesday, September 3, 2024 at 8:00 a.m. ET
Webcast: LINK
A replay of the presentation will be posted, when available, to Praxis’ website on the “Events and Presentations” page under the investor section of the website.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When will Praxis Precision Medicines (PRAX) announce the EMBOLD study results?
What is the EMBOLD study investigating for Praxis Precision Medicines (PRAX)?
How can investors access the Praxis Precision Medicines (PRAX) conference call on September 3, 2024?
What phase is the EMBOLD study of relutrigine (PRAX-562) by Praxis Precision Medicines (PRAX)?
